Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.eclinm.2020.100549 http://scihub22266oqcxt.onion/10.1016/j.eclinm.2020.100549 33073216!7550257!33073216     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33073216&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       EClinicalMedicine 2020 ; 27 (?): 100549 Nephropedia Template TP {{tp|p=33073216|t=2020. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study |pdf=|usr=}}{{33073216}} gab.com Text Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study JO: EClinicalMedicine http://www.kidney.de/pget.php?&tw=1&pmid=33073216 #FOAvip BACKGROUND: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality. METHODS: This retrospective multicentric cohort study used the Programme de Medicalisation des Systemes d'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts. FINDINGS: Eighty-nine patients were included. The median age was 67 years (range, 19-92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62-81%). In multivariable analysis, having an age >/= 70 years (hazard ratio 2.87, 1.20-6.85, p = 0.02) and relapsed/refractory lymphoma (hazard ratio 2.54, 1.14-5.66, p = 0.02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3.20, 1.33-7.72, p = 0.01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients < 70 years of age without relapsed/refractory lymphoma was 88% (78% - 99%). INTERPRETATION: Thirty-day mortality was associated with being older and relapsed/refractory lymphoma. Survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population. FUNDING: There have been no specific funds to run this study. Twit Text FOAVip Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study ????EClinicalMedicine http://www.kidney.de/pget.php?&tw=1&pmid=33073216 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33073216 #FOAvip English Wikipedia <ref>{{Cite pmid|33073216}}</ref> Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study #MMPMID33073216 Lamure S; Dulery R; Di Blasi R; Chauchet A; Laureana C; Deau-Fischer B; Drenou B; Soussain C; Rossi C; Noel N; Choquet S; Bologna S; Joly B; Kohn M; Malak S; Fouquet G; Daguindau E; Bernard S; Thieblemont C; Cartron G; Lacombe K; Besson C EClinicalMedicine 2020[Oct]; 27 (?): 100549 PMID33073216show ga BACKGROUND: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality. METHODS: This retrospective multicentric cohort study used the Programme de Medicalisation des Systemes d'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts. FINDINGS: Eighty-nine patients were included. The median age was 67 years (range, 19-92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62-81%). In multivariable analysis, having an age >/= 70 years (hazard ratio 2.87, 1.20-6.85, p = 0.02) and relapsed/refractory lymphoma (hazard ratio 2.54, 1.14-5.66, p = 0.02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3.20, 1.33-7.72, p = 0.01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients < 70 years of age without relapsed/refractory lymphoma was 88% (78% - 99%). INTERPRETATION: Thirty-day mortality was associated with being older and relapsed/refractory lymphoma. Survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population. FUNDING: There have been no specific funds to run this study. ?Determinants of outcome in Covid-19 hospitalized patients with lymphom(epmc).pdf DeepDyve Pubget Overpricing